Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin

Coronary Artery Disease

Volumn 23, Issue 5, 2012, Pages 315-321

  Iwata, Atsushi ^a   Miura, Shin Ichiro ^a   Tanaka, Tohru ^a   Ike, Amane ^a   Sugihara, Makoto ^a   Nishikawa, Hiroaki ^a   Kawamura, Akira ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

coronary plaque vulnerability; pentraxin 3; statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTRAXIN 3;

AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY PLAQUE VULNERABILITY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOWN-REGULATION; FEMALE; FIBROSIS; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; LIPIDS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PYRROLES; SERUM AMYLOID P-COMPONENT; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; URIC ACID;

EID: 84863723166     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328352ffec     Document Type: Article

References (19)

1. Prasado K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24:33-50.
2. Jylhävä J, Haarala A, Kähö nen M, Lehtimä ki T, Jula A, Moilanen L, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011; 164:211-217.
3. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215:48-55.
4. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27:161-167.
5. Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32:625-630.
6. Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, Onda R. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009; 16:490-500.
7. Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011; 58:151-157.
8. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102:636-641.
9. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110:2349-2354.
10. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004; 110:1061-1068.
11. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54:293-302.
12. Soeda T, Uemura S, Okayama S, Kawakami R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques. Evaluation using dual-source computed tomography. Circ J 2011; 75:2621-2627.
13. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, et al. Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound. Circ J 2011; 75:1448-1454.
14. Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, Onda R. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009; 16:490-500.
15. Yokota K, Miyoshi F, Sato K, Asanuma Y, Akiyama Y, Mimura T. Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners. Clin Exp Rheumatol 2011; 29:43-49.
16. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 2004; 11:62-72.
17. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227: 9-18.
18. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22:e10-e14.
19. Yilmaz MI, Carrero JJ, Mart?́n-Ventura JL, Sonmez A, Saglam M, Celik T, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5:1174-1181.